CTOs on the Move


 
Optimizing drug development with innovative instruments & scientific expertise.
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million

Executives

Name Title Contact Details

Similar Companies

PBN Pharma

PBN Pharma is a Chicago, IL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

CPEX Pharmaceuticals

CPEX Pharmaceuticals is a Exeter, NH-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Panacea Pharmaceuticals

Panacea Pharmaceuticals is a Gaithersburg, MD-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Action Behavior Centers

Founded in 2017, Action Behavior Centers (ABC) is a leading Applied Behavior Therapy (ABA) provider offering comprehensive services and support to improve the lives of children on the autism spectrum. The provider`s high-quality, center-based care combined with its dedication to helping young children reach their full potential has made ABC one of the fastest growing and highest quality providers in the industry. Headquartered in Austin, Texas, ABC operates 54 clinics in Texas, Arizona and Colorado.

Respira Therapeutics

Respira Therapeutics, Inc., founded in 2010 with offices in Albuquerque, New Mexico, is a development stage inhaled pharmaceutical development company focused on commercializing its "best in class", high efficiency AOS-DPI, dry powder inhaler (DPI) drug delivery technology to deliver RT234, a proprietary inhaled formulation of an off patent oral drug via the lung to treatment of multiple orphan indications in the fields of pulmonary hypertension and other diseases. Investors in Respira include Cottonwood Technology Fund and Sun Mountain Capital and individual investors. To date Respira has performed extensive testing demonstrating its advanced AOS-DPI prototypes can deliver 2-3X more drug to the lung than commercially available DPI technologies. Respira is planning proof of concept clinical trials of an inhaled formulation of RT234 in pulmonary arterial hypertension patients in the near future.